Details about Yawen Jiang

Access statistics for papers by Yawen Jiang.

Last updated 2024-01-06. Update your information in the RePEc Author Service.

Short-id: pji261

Journal Articles

2024

1. Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission–Economic Evaluation Model
   PharmacoEconomics, 2024, 42, (10), 1111-1125

2023

2. Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis
   Applied Health Economics and Health Policy, 2023, 21, (3), 489-499

2022

3. Does supplemental private health insurance incentivize household risky financial asset investment? Evidence from the China Household Financial Survey
   International Journal of Health Economics and Management, 2022, 22, (4), 369-421
4. Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life
   The European Journal of Health Economics, 2022, 23, (4), 607-615 View citations (2)
5. Quality of life and cost consequence of delays in endovascular treatment for acute ischemic stroke in China
   Health Economics Review, 2022, 12, (1), 1-8 View citations (2)

2020

6. Impact of supplementary private health insurance on hospitalization and physical examination in China
   China Economic Review, 2020, 63, (C) View citations (3)

2019

7. Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease
   PharmacoEconomics, 2019, 37, (7), 943-952
8. Risk selection into supplemental private health insurance in China
   Health Economics Review, 2019, 9, (1), 1-11 View citations (3)